Search

Displaying results 6971 - 6980 of 8468 in total
  1. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

  2. Drug

    Trodusquemine

    go.drugbank.com/drugs/DB06333
    Investigational

    It has demonstrated the ability to stimulate regeneration of heart and multiple other tissues in animal models [A176600].

  3. Drug

    CDX-1135

    go.drugbank.com/drugs/DB17607
    Investigational

    It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage.

  4. Drug

    2'-fluoro-5-ethylarabinosyluracil

    go.drugbank.com/drugs/DB13030
    Investigational

    2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine Lymphoma, Stage IV Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Splenic Marginal Zone Lymphoma

  5. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease.

  6. Drug

    Detirelix

    go.drugbank.com/drugs/DB19488
    Experimental

    Detirelix has a monoisotopic molecular weight of 1536.78 Da.

  7. Drug

    Xantocillin

    go.drugbank.com/drugs/DB19495
    Experimental

    Xantocillin has a monoisotopic molecular weight of 288.09 Da.

  8. Drug

    Sematilide

    go.drugbank.com/drugs/DB19538
    Experimental

    Sematilide has a monoisotopic molecular weight of 313.15 Da.

  9. Drug

    Terdecamycin

    go.drugbank.com/drugs/DB19720
    Experimental

    Terdecamycin has a monoisotopic molecular weight of 585.31 Da.

  10. Drug

    Paraxazone

    go.drugbank.com/drugs/DB19726
    Experimental

    Paraxazone has a monoisotopic molecular weight of 206.07 Da.